Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Reviva Pharmaceuticals Holdings Inc.(RVPH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RVPH
09/14/2026: RVPH (1-star) is currently NOT-A-BUY. Pass it for now.
Reviva Pharmaceuticals is a clinical-stage biotechnology firm developing small-molecule therapeutics for CNS and inflammatory disorders. The company's primary strength lies in its proprietary discovery platform and the late-stage development of its lead candidate, brilaroxazine. Its main investment story centers on the potential regulatory approval of this candidate, which could address significant gaps in schizophrenia treatment. Investors should be aware of high risks, including the company's pre-revenue status, reliance on equity financing, and intense competition from established pharmaceutical players. This stock best suits investors with a high risk tolerance who are specifically looking for exposure to binary clinical trial outcomes and biotech development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company represents a speculative growth opportunity tied to clinical trial outcomes rather than proven commercial growth. |
| Momentum investor | Mixed fit | Momentum investors may find interest during clinical data readouts, but the stock lacks consistent trend-based performance. |
| Value investor | Weak fit | The company lacks current earnings or traditional value metrics to support a fundamental valuation thesis. |
| Dividend investor | Weak fit | Reviva is a pre-revenue biotechnology company that does not pay dividends. |
| Low-risk investor | Weak fit | High volatility and clinical trial risk make this an unsuitable choice for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks frequently experience sharp price movements based on news, trial results, and market sentiment. |
| Valuation risk | High | Valuation is speculative and heavily dependent on future regulatory success and successful commercialization. |
| Competition risk | High | The company faces significant competition from large pharmaceutical incumbents in the CNS and schizophrenia treatment space. |
| Business quality | Medium | While the scientific pipeline shows promise, the lack of commercialized products limits the current quality of the business franchise. |
| Dividend income | Low / none | The company does not provide income to shareholders. |
| Execution risk | High | Success depends entirely on the company's ability to navigate complex clinical trials and achieve FDA approval. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -83.49% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/14/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.01M USD | Price to earnings Ratio - | 1Y Target Price 17.5 |
Price to earnings Ratio - | 1Y Target Price 17.5 | ||
Volume (30-day avg) 30.1K shares | Beta 0.5 | 52 Weeks Range 0.26 - 17.20 | Updated Date 09/13/2026 |
52 Weeks Range 0.26 - 17.20 | Updated Date 09/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.03 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Researching and developing drugs like brilaroxazine. | The company currently spends money to develop products; it does not yet earn revenue from sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -12.73M | Price to Sales(TTM) - |
Enterprise Value -12.73M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6 | Shares Outstanding 13.11M | Shares Floating 11.86M |
Shares Outstanding 13.11M | Shares Floating 11.86M | ||
Percent Insiders 7.73 | Percent Institutions 8.24 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Reviva Pharmaceuticals Holdings Inc.
Exchange NASDAQ | Headquarters Cupertino, CA, United States | ||
IPO Launch date 2018-10-18 | Founder, CEO, President & Director Dr. Laxminarayan Bhat Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.revivapharma.com |
Full time employees 14 | Website https://www.revivapharma.com | ||
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.